Skip to main content

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Completed · Phase 2, Phase 3 · NCT04887870

Conditions: Advanced or Metastatic Solid Malignancies

At a glance

Research payments reported, 2025
$1.7M
U.S. investigators named
8
Sites paid
8
Planned or actual enrollment
49

About the trial

Sponsor
Mirati Therapeutics Inc.
Tested
Sitravatinib (drug), Nivolumab (drug), Pembrolizumab (drug), Enfortumab Vedotin-Ejfv (drug), Ipilimumab (drug)
Dates
Started 2021-06-29; completion 2025-09-25
Results posted
Yes

A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies

From ClinicalTrials.gov, last updated 2026-08-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Mirati Therapeutics, Inc. reported $1.7M in research payments for this study in 2025 (8 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Ut MD Anderson Cancer Center $899,075
  • Next Oncology $561,268
  • New Experimental Therapeutics of San Antonio Llc $75,885
  • Regents of the University of Minnesota $55,580
  • Karmanos Cancer Center, MI $22,998
  • Texas Onco Southwest Fort Worth $21,435
  • Gu Research Network, Llc $12,664
  • Dana-Farber Cancer Institute $1,790

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.